Bazedoxifene Acetate

DRUG3 trials

Sponsors

Pfizer, Riley Bove, MD, The Alfred

Conditions

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingOsteoporosisSchizo Affective DisorderSchizophreniaSchizophreniform Disorders

Phase 2

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

CompletedNCT04002934

Riley Bove, MDMultiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting

Start: 2019-09-10End: 2025-05-20Updated: 2025-06-08

Phase 3

Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women

CompletedNCT00205777

PfizerOsteoporosis

Start: 2001-12-31End: 2010-09-30Updated: 2013-04-10

Phase 4

Bazedoxifene -Treatment for Women With Schizophrenia

RecruitingNCT04113993

The AlfredSchizo Affective Disorder, Schizophrenia, Schizophreniform Disorders

Start: 2019-10-07End: 2026-12-31Target: 160Updated: 2026-06-03

Related Papers

Re-WRAP (Remyelination for women at risk of axonal loss and progression): A phase II randomized placebo-controlled delayed-start trial of bazedoxifene for myelin repair in multiple sclerosis.

2023-09-2010 citations

Well-being at midlife: Correlates of mental health in ambulatory menopausal women with multiple sclerosis

Multiple Sclerosis Journal2023-09-1612 citations

Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.

2010-06-2260 citations